Header Logo

Connection

ANNE TSAO to Biomarkers, Tumor

Back to Details
This is a "connection" page, showing publications ANNE TSAO has written about Biomarkers, Tumor.
ANNE TSAO
Connection Strength
0.990
Biomarkers, Tumor
  1. Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. J Thorac Oncol. 2013 May; 8(5):658-61.
    View in: PubMed
    Score: 0.113
  2. Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. J Thorac Oncol. 2012 Nov; 7(11):1645-52.
    View in: PubMed
    Score: 0.109
  3. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol. 2011 Dec; 6(12):2104-11.
    View in: PubMed
    Score: 0.102
  4. Mesothelioma and small cell lung cancer. J Thorac Oncol. 2011 Nov; 6(11 Suppl 4):S1825-6.
    View in: PubMed
    Score: 0.102
  5. The American Cancer Society National Lung Cancer Roundtable strategic plan: Methods for improving turnaround time of comprehensive biomarker testing in non-small cell lung cancer. Cancer. 2024 Dec 15; 130(24):4200-4212.
    View in: PubMed
    Score: 0.062
  6. C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome. Leuk Res. 2004 Apr; 28(4):373-8.
    View in: PubMed
    Score: 0.060
  7. Identification of distinct immune landscapes using an automated nine-color multiplex immunofluorescence staining panel and image analysis in paraffin tumor tissues. Sci Rep. 2021 02 25; 11(1):4530.
    View in: PubMed
    Score: 0.049
  8. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019 09; 69(5):402-429.
    View in: PubMed
    Score: 0.043
  9. Pathologic Considerations and Standardization in Mesothelioma Clinical Trials. J Thorac Oncol. 2019 10; 14(10):1704-1717.
    View in: PubMed
    Score: 0.043
  10. Updates in Local-Regionally Advanced Non-Small Cell Lung Cancer. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:553-562.
    View in: PubMed
    Score: 0.043
  11. Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discov. 2018 12; 8(12):1548-1565.
    View in: PubMed
    Score: 0.041
  12. Current readings: Window-of-opportunity trials for thoracic malignancies. Semin Thorac Cardiovasc Surg. 2014; 26(4):323-30.
    View in: PubMed
    Score: 0.032
  13. Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma. Ann Diagn Pathol. 2014 Jun; 18(3):140-5.
    View in: PubMed
    Score: 0.030
  14. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res. 2013 Dec 15; 19(24):6967-75.
    View in: PubMed
    Score: 0.029
  15. Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial. J Thorac Oncol. 2013 Apr; 8(4):436-42.
    View in: PubMed
    Score: 0.028
  16. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011 Jun; 1(1):44-53.
    View in: PubMed
    Score: 0.025
  17. Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen. J Thorac Oncol. 2009 Jun; 4(6):689-96.
    View in: PubMed
    Score: 0.022
  18. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol. 2008 Mar 20; 26(9):1472-8.
    View in: PubMed
    Score: 0.020
  19. Chemoprevention of cancer. CA Cancer J Clin. 2004 May-Jun; 54(3):150-80.
    View in: PubMed
    Score: 0.015
  20. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514.
    View in: PubMed
    Score: 0.012
  21. Consensus Report of the 2015 Weinman International Conference on Mesothelioma. J Thorac Oncol. 2016 08; 11(8):1246-1262.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.